Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors

Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors

Background: Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African pa...

Full description

Bibliographic Details
Main Authors:	F. Ben Mbarka, K. Ben Jeddou, E. Allouche, I. Boukhris, N. Khalfallah, H. Baccar, Z. Ouahchi
Format:	Article
Language:	English
Published:	SpringerOpen 2018-03-01
Series:	The Egyptian Heart Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S1110260817302119

Similar Items

Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding.
by: Paola E J van der Meijden, et al.
Published: (2013-01-01)

Bleedings caused by warfarin overdose
by: Erdem Çevik, et al.
Published: (2014-06-01)

Bleedings caused by warfarin overdose
by: Orhan Alimoğlu, et al.
Published: (2012-06-01)

The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis
by: Kuang-Tsu Yang, et al.
Published: (2021-12-01)

Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
by: Fernando Pivatto Júnior, et al.
Published: (2015-07-01)

Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
by: Fernando Pivatto Júnior, et al.
Published: (2015-07-01)

Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
by: Xiaojuan Wu, et al.
Published: (2021-09-01)

Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies
by: Larisa Anghel, et al.
Published: (2020-05-01)

Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing.
by: Saartje Bloemen, et al.
Published: (2017-01-01)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
by: Daniele Pastori, et al.
Published: (2018-04-01)

Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis.
by: Joel Skaistis, et al.
Published: (2015-01-01)

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
by: Nienke van Rein, et al.
Published: (2016-01-01)

Vitamin K Deficiency Bleeding in Infancy
by: Shunsuke Araki, et al.
Published: (2020-03-01)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
by: Frederique E. C. M. Peeters, et al.
Published: (2018-10-01)

Characteristics, Location, and Clinical Outcomes of Gastrointestinal Bleeding in Patients Taking New Oral Anticoagulants Compared to Vitamin K Antagonists
by: A Reum Choe, et al.
Published: (2021-06-01)

Vitamin K antagonists after all, or possibly not?
by: Victor Machado Gil
Published: (2016-09-01)

Major bleeding risk with non‐vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta‐analysis
by: Wen‐Yi Huang, et al.
Published: (2020-12-01)

Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists
by: Giancarlo Landini, et al.
Published: (2013-12-01)

Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
by: Jannik Langtved Pallisgaard, et al.
Published: (2016-01-01)

Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists?
by: Martin Müller, et al.
Published: (2021-04-01)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
by: Giovanni Luca Botto, et al.
Published: (2021-06-01)

Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists in 649 fast-track total hip and knee arthroplasties
by: Christoffer C Jørgensen, et al.
Published: (2017-01-01)

Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database
by: Young-Jin Ko, et al.
Published: (2019-09-01)

Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study
by: Raza Alikhan, et al.
Published: (2019-10-01)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
by: Lessire Sarah, et al.
Published: (2014-01-01)

Management of Calcium Channel Antagonist Overdose with Hyperinsulinemia-Euglycemia Therapy: Case Series and Review of the Literature
by: Shiwan K. Shah, et al.
Published: (2012-01-01)

Non-Vitamin K Antagonist Oral Anticoagulants A Concise Guide
Published: (2016)

Communication publique : ancrage des TIC dans l'organisation : étude de cas : l'administration tunisienne
by: Ben Jeddou, Sameh
Published: (2015)

Management of lercanidipine overdose with hyperinsulinaemic euglycaemia therapy: case report
by: Messer Ben, et al.
Published: (2011-01-01)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
by: Sarah Lessire, et al.
Published: (2014-01-01)

Non-vitamin K Antagonist Oral Anticoagulants: Practise Essentials
by: Joana de Lemos Barata Garcia
Published: (2019)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
by: Mark Terence P. Mujer, et al.
Published: (2020-01-01)

Extent of arterial calcification by conventional vitamin K antagonist treatment.
by: Selma Hasific, et al.
Published: (2020-01-01)

Non-vitamin K antagonist oral anticoagulants for heart diseases
by: T B Kondratieva, et al.
Published: (2017-09-01)

Strain differences in toxicity of vitamin K antagonist warfarin in rats
by: Đokić Jelena, et al.
Published: (2013-01-01)

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
by: Emma Kirstine Laugesen, et al.
Published: (2019-11-01)

Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage
by: Szu-Ju Chen, et al.
Published: (2020-01-01)

Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study
by: Lihong Tang, et al.
Published: (2020-06-01)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
by: Craig I. Coleman, et al.
Published: (2019-01-01)

Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes
by: Thorsten Steiner, et al.
Published: (2018-09-01)